A large language model (LLM)-based multi-agent framework for risk stratification and treatment recommendations in localized prostate cancer (locPCa).
Abstract
5108 Background: We previously proposed a hybrid framework combining LLMs and rule based algorithm (RBA) for automating risk stratification in locPCa. Herein, we aim to validate the risk stratification agent (RSA) in a prospective cohort, develop & evaluate the treatment recommendation agent (TRA) based on NCCN guidelines, and develop an interactive interface to facilitate clinicians for accurate risk stratification and treatment recommendations at the point of care. Methods: This study included pts with locPCa (2004-2024) presenting at Mayo Clinic with at least 1 positive prostate biopsy and MRI report available. For RSA prospective validation, GPT4 extracted key phenotypic variables (PSA, T stage, prostate volume, number of cores, Gleason patterns, grade group) from unstructured MRI and biopsy reports using a zeroshot prompt. An RBA then classified pts into NCCN risk groups. The agent performance was compared with the treating clinician's documentation and evaluated against gold-standard labels manually annotated by two independent clinicians. For development of TRA, two experiments were performed using GPT4 with and without retrieval-augmented generation (RAG) to generate treatment plans. Generated treatment plans were evaluated using NCCN guideline-informed treatment decision tree based algorithm (DTA). Evaluation metrics, weighted – accuracy (acc) and F1, were computed. A clinician facing interface (lisr.org/risk) was developed to provide accurate risk stratification and treatment plans. Results: A total of 858 pts were included (500 for prospective validation, 358 for treatment recommendations). Prospective validation for RSA demonstrated a higher F1 score of 0.89 compared to the treating clinician (F1: 0.58). Treatment recommendation experiments showed that GPT4 with RAG achieved higher acc (64% full – all correct treatment options and 36% partial – at least 1 correct treatment option) compared to GPT4 alone (35% and 65%, respectively). Sensitivity analysis using DTA-informed GPT4 note generation achieved 94% full acc and 6% partial acc. GPT4 alone generated hallucinated treatment options in 71% of cases, while GPT4 with RAG reduced this to 32%. Conclusions: The multi-agent framework based on LLM and RBA achieves high accuracy in risk stratification and treatment recommendation for locPCa. A multi-agent framework with an interactive interface holds high promise to enable efficient, accurate decision-making, and improve locPCa management at the point of care Performance evaluation. RSA(acc; F1) % TRA(full acc; partial acc) % Clinician RSA* GPT4 RAG+GPT4 DTA+GPT4 Overall 60; 58 89; 89 29; 71 64; 36 94; 6 V. High 94; 33 96; 96 55; 45 69; 31 93; 7 High 46; 52 92; 89 - - - Int. Unf 80; 61 91; 90 5; 95 38; 62 93; 7 Int. Fav 57; 64 84; 87 0; 100 98; 2 100; 0 Low 57; 65 87; 80 100; 0 95; 5 90; 10 V. Low 8; 13 50; 67^ - - - *Statistical significance (p<0.01) except for ^V. Low.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (19)
Umair Ayub
1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States
Syed Arsalan Ahmed Naqvi
Mayo Clinic, Phoenix, AZ
Salman Ayub Jajja
NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States
Muhammad Umar Afzal
Mayo Clinic Arizona, Scottsdale, AZ
Ji-Eun Irene Yum
Mayo Clinic Alix School of Medicine, Phoenix, AZ
Kaneez Zahra Rubab Khakwani
University of Arizona, Tucson, AZ
Chitta Baral
Arizona State Univeristy (ASU), Tempe, AZ
Sumanta Kumar Pal
Department of Medical Oncology City of Hope Comprehensive Cancer Center Duarte California USA
Neeraj Agarwal
Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA
Abhishek Tripathi
Department of Medical Oncology and Therapeutics Research City of Hope Comprehensive Cancer Center Duarte California USA
Jack Andrews
Mayo Clinic Arizona, Phoenix, AZ
Haidar Abdul-Muhsin
Mayo Clinic Arizona, Phoenix, AZ
Daniel M. Frendl
Mayo Clinic Arizona, Phoenix, AZ
Mark Raymond Waddle
Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, MN
Daniel S Childs
Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN
Alan Haruo Bryce
Mayo Clinic Arizona, Phoenix, AZ
Yousef Zakharia
Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA
Parminder Singh
Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ
Irbaz Bin Riaz
Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA